Literature DB >> 26104939

Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.

Daniel J Krauss1, Chen Hu2, Jean-Paul Bahary3, Luis Souhami4, Elizabeth M Gore5, Susan Maria Jacinta Chafe6, Mark H Leibenhaut7, Samir Narayan8, Javier Torres-Roca9, Jeff Michalski10, Kenneth L Zeitzer11, Viroon Donavanik12, Howard Sandler13, David G McGowan6, Christopher U Jones7, William U Shipley14.   

Abstract

PURPOSE: The purpose of this study was to assess the association between positive post-radiation therapy (RT) biopsy results and subsequent clinical outcomes in males with localized prostate cancer. METHODS AND MATERIALS: Radiation Therapy Oncology Group study 94-08 analyzed 1979 males with prostate cancer, stage T1b-T2b and prostate-specific antigen concentrations of ≤ 20 ng/dL, to investigate whether 4 months of total androgen suppression (TAS) added to RT improved survival compared to RT alone. Patients randomized to receive TAS received flutamide with luteinizing hormone releasing hormone (LHRH) agonist. According to protocol, patients without evidence of clinical recurrence or initiation of additional endocrine therapy underwent repeat prostate biopsy 2 years after RT completion. Statistical analysis was performed to evaluate the impact of positive post-RT biopsy results on clinical outcomes.
RESULTS: A total of 831 patients underwent post-RT biopsy, 398 were treated with RT alone and 433 with RT plus TAS. Patients with positive post-RT biopsy results had higher rates of biochemical failure (hazard ratio [HR] = 1.7; 95% confidence interval [CI] = 1.3-2.1) and distant metastasis (HR = 2.4; 95% CI = 1.3-4.4) and inferior disease-specific survival (HR = 3.8; 95% CI = 1.9-7.5). Positive biopsy results remained predictive of such outcomes after correction for potential confounders such as Gleason score, tumor stage, and TAS administration. Prior TAS therapy did not prevent elevated risk of adverse outcome in the setting of post-RT positive biopsy results. Patients with Gleason score ≥ 7 with a positive biopsy result additionally had inferior overall survival compared to those with a negative biopsy result (HR = 1.56; 95% CI = 1.04-2.35).
CONCLUSIONS: Positive post-RT biopsy is associated with increased rates of distant metastases and inferior disease-specific survival in patients treated with definitive RT and was associated with inferior overall survival in patients with high-grade tumors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26104939      PMCID: PMC4480595          DOI: 10.1016/j.ijrobp.2015.03.017

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Authors:  Christopher U Jones; Daniel Hunt; David G McGowan; Mahul B Amin; Michael P Chetner; Deborah W Bruner; Mark H Leibenhaut; Siraj M Husain; Marvin Rotman; Luis Souhami; Howard M Sandler; William U Shipley
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

2.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.

Authors:  Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-31       Impact factor: 7.038

3.  Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.

Authors:  Luis Souhami; Kyounghwa Bae; Miljenko Pilepich; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-29       Impact factor: 7.038

4.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

Authors:  Stephanie T H Peeters; Wilma D Heemsbergen; Peter C M Koper; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Johannes M G Bonfrer; Luca Incrocci; Joos V Lebesque
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

5.  Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.

Authors:  William U Shipley; Michelle Desilvio; Michael V Pilepich; Mack Roach; Harvey B Wolkov; William T Sause; Philip Rubin; Colleen A Lawton
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-19       Impact factor: 7.038

6.  The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome.

Authors:  Waseet Vance; Susan L Tucker; Renaud de Crevoisier; Deborah A Kuban; M Rex Cheung
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-08       Impact factor: 7.038

7.  Duration of androgen suppression in the treatment of prostate cancer.

Authors:  Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

8.  Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer.

Authors:  Michael J Zelefsky; Victor E Reuter; Zvi Fuks; Peter Scardino; Alison Shippy
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

9.  Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial.

Authors:  Juanita M Crook; Shawn Malone; Gad Perry; Libni Eapen; Julie Owen; Susan Robertson; Charles Ludgate; Sharon Fung; Gina Lockwood
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

10.  Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival.

Authors:  Wilma D Heemsbergen; Abrahim Al-Mamgani; Annerie Slot; Michel F H Dielwart; Joos V Lebesque
Journal:  Radiother Oncol       Date:  2013-11-15       Impact factor: 6.280

View more
  8 in total

1.  Long-Term Implications of a Positive Posttreatment Biopsy in Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.

Authors:  Michael J Zelefsky; Debra A Goldman; Victor Reuter; Marisa Kollmeier; Sean McBride; Zhigang Zhang; Melissa Varghese; Xin Pei; Zvi Fuks
Journal:  J Urol       Date:  2019-06       Impact factor: 7.450

2.  Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion.

Authors:  Daniel Gorovets; Andreas G Wibmer; Assaf Moore; Stephanie Lobaugh; Zhigang Zhang; Marisa Kollmeier; Sean McBride; Michael J Zelefsky
Journal:  Eur Urol Oncol       Date:  2022-03-17

3.  Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy.

Authors:  Alan Pollack; Felix M Chinea; Elizabeth Bossart; Deukwoo Kwon; Matthew C Abramowitz; Charles Lynne; Merce Jorda; Brian Marples; Vivek N Patel; Xiaodong Wu; Isildinha Reis; Matthew T Studenski; Javier Casillas; Radka Stoyanova
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-02-19       Impact factor: 7.038

4.  Positive prostate biopsy following radiotherapy can predict metastasis-free survival in localized prostate cancer.

Authors:  A Zapatero; M Adrados; L Torres; M S Talaya; A Cruz Conde; C Martin de Vidales; L Vega Piris; C Olivier; M T Murillo
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-09

5.  Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.

Authors:  I-Chow Hsu; Joseph P Rodgers; Katsuto Shinohara; James Purdy; Jeff Michalski; Mack Roach; Eric Vigneault; Robert A Ivker; Rodger M Pryzant; Michael Kuettel; Daniel Taussky; Gary S Gustafson; Adam Raben; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-10       Impact factor: 8.013

6.  Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.

Authors:  Antoine Kass-Iliyya; Gordana Jovic; Claire Murphy; Cyril Fisher; Isabel Syndikus; Chakiath Jose; Christopher D Scrase; John D Graham; David Nicol; Matthew R Sydes; David Dearnaley
Journal:  Eur Urol       Date:  2018-01-04       Impact factor: 20.096

7.  Implications of local failure on overall prognosis in aggressive prostate cancer.

Authors:  Layth Mula-Hussain; Soumyajit Roy; Shawn Malone
Journal:  Transl Androl Urol       Date:  2020-06

8.  Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis.

Authors:  Saurabh Singh; Caroline M Moore; Shonit Punwani; Anita V Mitra; Steve Bandula
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-08       Impact factor: 5.554

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.